Next Article in Journal
Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier
Next Article in Special Issue
The Neuronal Actions of Leptin and the Implications for Treating Alzheimer’s Disease
Previous Article in Journal
The Effect of Novel Oleanolic Acid Oximes Conjugated with Indomethacin on the Nrf2-ARE And NF-κB Signaling Pathways in Normal Hepatocytes and Human Hepatocellular Cancer Cells
Previous Article in Special Issue
Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer’s Disease
Review

Journey on Naphthoquinone and Anthraquinone Derivatives: New Insights in Alzheimer’s Disease

Dipartimento di Farmacia, Università degli Studi di Genova, Viale Benedetto XV, 3, 16132 Genova, Italy
*
Author to whom correspondence should be addressed.
These authors equally contributed to the study and both should be considered as first author.
Pharmaceuticals 2021, 14(1), 33; https://0-doi-org.brum.beds.ac.uk/10.3390/ph14010033
Received: 28 November 2020 / Revised: 27 December 2020 / Accepted: 30 December 2020 / Published: 5 January 2021
(This article belongs to the Special Issue Treatment of Alzheimer Disease)
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline leading to dementia and death. AD imposes neuronal death by the intricate interplay of different neurochemical factors, which continue to inspire the medicinal chemist as molecular targets for the development of new agents for the treatment of AD with diverse mechanisms of action, but also depict a more complex AD scenario. Within the wide variety of reported molecules, this review summarizes and offers a global overview of recent advancements on naphthoquinone (NQ) and anthraquinone (AQ) derivatives whose more relevant chemical features and structure-activity relationship studies will be discussed with a view to providing the perspective for the design of viable drugs for the treatment of AD. In particular, cholinesterases (ChEs), β-amyloid (Aβ) and tau proteins have been identified as key targets of these classes of compounds, where the NQ or AQ scaffold may contribute to the biological effect against AD as main unit or significant substructure. The multitarget directed ligand (MTDL) strategy will be described, as a chance for these molecules to exhibit significant potential on the road to therapeutics for AD. View Full-Text
Keywords: naphthoquinone/anthraquinone derivatives; Alzheimer’s disease (AD); Aβ aggregation inhibition; AChE and BChE inhibition; Tau inhibition; multitarget directed ligands naphthoquinone/anthraquinone derivatives; Alzheimer’s disease (AD); Aβ aggregation inhibition; AChE and BChE inhibition; Tau inhibition; multitarget directed ligands
Show Figures

Figure 1

MDPI and ACS Style

Campora, M.; Francesconi, V.; Schenone, S.; Tasso, B.; Tonelli, M. Journey on Naphthoquinone and Anthraquinone Derivatives: New Insights in Alzheimer’s Disease. Pharmaceuticals 2021, 14, 33. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14010033

AMA Style

Campora M, Francesconi V, Schenone S, Tasso B, Tonelli M. Journey on Naphthoquinone and Anthraquinone Derivatives: New Insights in Alzheimer’s Disease. Pharmaceuticals. 2021; 14(1):33. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14010033

Chicago/Turabian Style

Campora, Marta, Valeria Francesconi, Silvia Schenone, Bruno Tasso, and Michele Tonelli. 2021. "Journey on Naphthoquinone and Anthraquinone Derivatives: New Insights in Alzheimer’s Disease" Pharmaceuticals 14, no. 1: 33. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14010033

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop